BVSBioventus Inc.

Nasdaq bioventus.com


$ 9.55 $ -0.13 (-1.35 %)    

Friday, 06-Sep-2024 15:59:59 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 9.53
$ 9.53 x 200
-- x --
-- - --
$ 2.82 - $ 10.26
411,750
na
771.68M
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-29-2024 10-Q
2 05-07-2024 03-30-2024 10-Q
3 03-12-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 07-01-2023 10-Q
6 05-16-2023 04-01-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-21-2022 10-01-2022 10-Q
9 08-12-2022 07-02-2022 10-Q
10 05-11-2022 04-02-2022 10-Q
11 03-11-2022 12-31-2021 10-K
12 11-10-2021 10-02-2021 10-Q
13 08-11-2021 07-03-2021 10-Q
14 05-13-2021 04-03-2021 10-Q
15 03-26-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-bioventus-raises-price-target-to-12

Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $8 t...

 craig-hallum-maintains-buy-on-bioventus-raises-price-target-to-12

Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $9 to $12.

 bioventus-raises-2024-guidance-now-expects-net-sales-of-557m-567m-prior-535m-550m-vs-542767m-est-and-adj-eps-of-036-to-042-prior-025-to-033-vs-028-est

2024 Financial Guidance: Based on strong execution and momentum through the first half of 2024, Bioventus is raising financial...

 bioventus-q2-2024-adj-eps-019-beats-007-estimate-sales-151217m-beat-137595m-estimate

Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.07 by 171...

 canaccord-genuity-maintains-buy-on-bioventus-raises-price-target-to-8

Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 t...

 bioventus-raises-2024-guidance-now-expects-net-sales-of-535m-550m-prior-520m-535m-vs-528033m-est-and-adj-eps-of-025-to-033-prior-012-020-vs-016-est

2024 Financial Guidance: Based on strong execution and significant momentum across the business, Bioventus is raising financia...

 bioventus-q1-2024-adj-eps-007-beats-007-estimate-sales-129457m-beat-118380m-estimate

Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.07) by 2...

 blend-labs-reports-q4-results-joins-alta-equipment-despegarcom-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLN...

 craig-hallum-maintains-buy-on-bioventus-raises-price-target-to-9

Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $6 to $9.

 why-asana-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

 bioventus-reports-upbeat-earnings-joins-ranpak-beachbody-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were higher, with the Dow Jones index surging more than 200 points on Tuesday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION